Pfizer Future Growth

Future criteria checks 1/6

Pfizer is forecast to grow earnings and revenue by 16.8% and 0.8% per annum respectively. EPS is expected to grow by 16.9% per annum. Return on equity is forecast to be 17% in 3 years.

Key information

16.8%

Earnings growth rate

16.9%

EPS growth rate

Pharmaceuticals earnings growth	19.5%
Revenue growth rate	0.8%
Future return on equity	17.0%
Analyst coverage	Good
Last updated	20 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BASE:PFE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	63,589	12,291	17,010	19,962	21
12/31/2025	62,934	11,329	16,391	18,444	23
12/31/2024	62,598	9,214	8,604	16,073	23
9/29/2024	59,375	4,274	8,227	11,263	N/A
6/30/2024	55,166	-2,593	4,810	8,005	N/A
3/31/2024	54,889	-288	5,106	8,578	N/A
12/31/2023	58,496	2,134	4,793	8,700	N/A
10/1/2023	69,274	10,469	8,178	12,042	N/A
7/2/2023	78,420	21,494	10,665	14,560	N/A
4/2/2023	93,154	29,035	20,206	23,938	N/A
12/31/2022	100,330	31,366	26,031	29,267	N/A
10/2/2022	99,878	29,953	23,362	26,599	N/A
7/3/2022	101,275	29,481	28,440	31,454	N/A
4/3/2022	92,433	25,410	31,783	34,583	N/A
12/31/2021	81,288	22,413	29,869	32,580	N/A
10/3/2021	68,877	19,485	29,769	32,291	N/A
7/4/2021	55,119	12,236	21,141	23,552	N/A
4/4/2021	46,084	9,032	13,477	15,808	N/A
12/31/2020	41,651	6,630	12,177	14,403	N/A
9/27/2020	32,334	212	10,512	12,547	N/A
6/28/2020	34,737	6,977	12,777	14,967	N/A
3/29/2020	38,137	9,427	11,702	14,023	N/A
12/31/2019	40,905	10,707	10,542	12,588	N/A
9/29/2019	53,039	16,211	10,897	13,557	N/A
6/30/2019	53,656	12,638	11,746	14,306	N/A
3/31/2019	53,859	11,464	13,146	15,542	N/A
12/31/2018	40,825	3,824	13,691	15,827	N/A
9/30/2018	53,373	23,808	16,001	18,178	N/A
7/1/2018	53,244	22,545	N/A	17,808	N/A
4/1/2018	52,673	21,746	N/A	17,201	N/A
12/31/2017	52,546	21,305	N/A	16,802	N/A
10/1/2017	52,471	9,791	N/A	15,463	N/A
7/2/2017	52,347	8,308	N/A	15,311	N/A
4/2/2017	52,598	7,281	N/A	15,677	N/A
12/31/2016	52,824	7,198	N/A	16,192	N/A
10/2/2016	53,243	6,270	N/A	15,049	N/A
7/3/2016	52,286	7,036	N/A	15,332	N/A
4/3/2016	50,992	7,615	N/A	15,816	N/A
12/31/2015	48,851	6,948	N/A	14,688	N/A
9/27/2015	47,922	8,366	N/A	15,188	N/A
6/28/2015	48,196	8,913	N/A	14,631	N/A
3/29/2015	49,116	9,200	N/A	14,628	N/A
12/31/2014	49,605	9,085	N/A	17,084	N/A
9/28/2014	50,045	10,461	N/A	17,209	N/A
6/29/2014	50,327	10,370	N/A	18,646	N/A
3/30/2014	50,527	10,994	N/A	18,316	N/A
12/31/2013	51,584	11,339	N/A	17,684	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PFE's forecast earnings growth (16.8% per year) is above the savings rate (8.7%).

Earnings vs Market: PFE's earnings (16.8% per year) are forecast to grow slower than the AR market (19.3% per year).

High Growth Earnings: PFE's earnings are forecast to grow, but not significantly.

Revenue vs Market: PFE's revenue (0.8% per year) is forecast to grow slower than the AR market (13.9% per year).

High Growth Revenue: PFE's revenue (0.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PFE's Return on Equity is forecast to be low in 3 years time (17%).

Pfizer Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Recent updates

Pfizer Inc. Announces Executive Changes

Pfizer Reportedly Explore Sale of Hospital Drugs Unit

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Pfizer Inc. Announces Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

Pfizer Inc. Announces Election of Mortimer J. Buckley to Its Board of Directors

U.S. FDA Approves Pfizer Inc.’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

Pfizer Inc. Announces Positive Topline Results from the Final Prespecified Overall Survival Analysis of the TALAPRO-2 Study of TALZENNA®

Starboard Value Wants Pfizer to Make Changes to Turn its Performance Around

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

Pfizer Inc. to Report Q3, 2024 Results on Oct 29, 2024

Pfizer Announces its BRAFTOVI + MEKTOVI Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

Pfizer Appoints Elif Aral as Regional President for Middle East, Russia, and Africa (MERA)

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Pfizer Inc. Launches PfizerForAll

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

Pfizer Inc Announces Results of ABRYSVO® for RSV in Immunocompromised Adults

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies